Firm
Law firms are rethinking litigation strategies after USPTO director John Squires said he would take control of PTAB challenges
In major recent developments, the court also ruled on another request concerning access to documents and appointed a new panel to the Court of Appeal
A new foundation in Chile is giving women in the IP community the mentorship, and visibility they’ve long lacked
Åsa Gustafson, global patent paralegal manager at Zacco, provides insight into the world of a paralegal, explains how she keeps abreast of legal developments, and reveals a passion for weaving
Sponsored
Sponsored
-
Sponsored by Saint Island International Patent & Law OfficesTony Tung-Yang Chang of Saint Island International Patent & Law Offices says plant variety holders will have welcomed the ruling, which resolves previous divergence in local courts over the methodology for assessing infringement -
Sponsored by RNA, Technology and IP AttorneysRanjan Narula and Eeshani Sharma of RNA, Technology and IP Attorneys explain how India’s legal framework applies to video game characters and question whether it needs to ‘level up’, given the industry’s rapid evolution
-
Sponsored by Maiwald Intellectual PropertyWilhelm Eger of Maiwald Intellectual Property examines how the Pemetrexed case has influenced European approaches to patent infringement under the doctrine of equivalency and how numbers and measurements are addressed
-
Sponsored by Uni-intel Patent and Trademark Law FirmGump Wang of Uni-intel Patent and Trademark Law Firm explores the strategic value of utility models, which have strong enforcement potential and play a crucial role in China’s patent system
-
Sponsored by AFD China Intellectual Property Law OfficeLinlin Sun and Xia Zheng of AFD China Intellectual Property Law Office cite two key Chinese Supreme People’s Court cases to clarify the conditions under which supplementary experimental data is accepted
-
Sponsored by DEQI Intellectual Property Law CorporationChen Shihua of DEQI Intellectual Property Law Corporation explains China's patent term compensation system, which includes a patent term adjustment for delays and a patent term extension for pharmaceutical patents requiring regulatory approval
